Sydney Stewart, Author at BioTuesdays

Developments

Novavax sets first-in-human trial for coronavirus vaccine candidate in mid-May

Novavax (NASDAQ:NVAX) identified a coronavirus vaccine candidate, NVX-CoV2373, using its nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’s Matrix-M adjuvant will be incorporated...

April 8, 2020

Markets

Maxim ups AIM ImmunoTech PT to $5 from $2

Maxim Group raised its price target for AIM ImmunoTech (NYSE American:AIM) to $5 from $2, citing a strengthened balance sheet and a $14.54-million award from the NCI to study its Ampligen drug candidate in up to five...

April 6, 2020

Markets

HCW starts Molecular Partners at buy; PT CHF29

H.C. Wainwright initiated coverage of Swiss-based Molecular Partners (SWX:MOLN) with a “buy” rating and price target of CHF29. The stock closed at CHF17.54 on April 1. Molecular Partners is developing targeted therapies...

April 2, 2020

Developments

FDA accepts Mesoblast BLA for RYONCIL; agrees to priority review

The FDA accepted for priority review Mesoblast’s (NASDAQ:MESO; ASX:MSB) biologics license application filing for RYONCIL, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft...

April 1, 2020

Developments

Zucara Therapeutics in $21-million Series A funding led by Perceptive Xontogeny

Closely held Zucara Therapeutics closed a $21-million Series A financing led by the Perceptive Xontogeny Venture (PXV) Fund. Proceeds will be used for Phase 1 and Phase 2 clinical trials of ZT-01, Zucara’s first-in...

March 31, 2020

Markets

HCW starts AB Science at buy; PT €9.00

H.C. Wainwright initiated coverage of AB Science (Euronext – FR0010557264 – AB) with a “buy” rating and price target of €9.00. The stock closed at €6.78 on March 27. AB Science’s lead product, masitinib, is...

March 30, 2020

Developments

Kasraeian Urology treats first Jacksonville patient with Profound’s TULSA-PRO

Dr. Ali Kasraeian of the renowned Kasraeian Urology in Jacksonville, FL, in partnership with Vituro Health, treated their first patient with Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO medical device for...

March 27, 2020

Markets

Stifel starts Molecular Templates at buy; PT $19

Stifel initiated coverage of Molecular Templates (NASDAQ:MTEM) with a “buy” rating and $19 price target. The stock closed at $13.29 on March 24. “We believe the engineered toxin body technology from which Molecular’s...

March 25, 2020

Developments

NantKwest doses first patient in Phase 2 Merkel cell carcinoma study

NantKwest (NASDAQ:NK) dosed the first patient in its Phase 2 trial for second- and third-line Merkel cell carcinoma (MCC). MCC is a rare and aggressive skin cancer that is fatal for the majority of patients who have...

March 19, 2020

Markets

Stifel cuts DBV Technologies to hold; PT to $6 from $18

Stifel downgraded DBV Technologies (NASDAQ:DBVT) to “hold” from “buy” and slashed its price target to $6 from $18 after the FDA raised questions about DBV’s Viaskin Peanut’s efficacy, including the impact of patch...

March 17, 2020

Author - Sydney Stewart

Novavax sets first-in-human trial for coronavirus vaccine candidate in mid-May

Maxim ups AIM ImmunoTech PT to $5 from $2

HCW starts Molecular Partners at buy; PT CHF29

FDA accepts Mesoblast BLA for RYONCIL; agrees to priority review

Zucara Therapeutics in $21-million Series A funding led by Perceptive Xontogeny

HCW starts AB Science at buy; PT €9.00

Kasraeian Urology treats first Jacksonville patient with Profound’s TULSA-PRO

Stifel starts Molecular Templates at buy; PT $19

NantKwest doses first patient in Phase 2 Merkel cell carcinoma study

Stifel cuts DBV Technologies to hold; PT to $6 from $18

Subscribe